Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia

Neoplasma

Volumn 47, Issue 2, 2000, Pages 125-128

  Tothova E ^a   Fricova M ^a   Kafkova A ^a   Stecova N ^a   Guman, T ^a   Raffac S ^a   Hlebaskova M ^a  

^a FACULTY HOSPITAL   (Slovakia)

Author keywords

Chronic myeloid leukemia; Cytarabin; Cytogenetic response; Hematologic response; Interferon

Indexed keywords

ALPHA2B INTERFERON; AMINOTRANSFERASE; CYTARABINE; HYDROXYUREA; LIVER ENZYME;

ADULT; ARTICLE; CANCER REGRESSION; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; CYTOPENIA; DEPRESSION; FEMALE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; LIVER TOXICITY; MALE; METAPHASE CHROMOSOME; MULTICENTER STUDY; NEUROTOXICITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN TOXICITY;

EID: 0343091317     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. AGAPE, P., MAHON, F., MARIT, G.: All-trans retinoic acid combined with interferon alpha in chronic myeloid leukemia: Results of a pilot study. Leukemia, 11, 1997, 1391-1397.
2. ARTHUR, C.K., MA, D.F.: Combined interferon alfa 2a cytosine arabinoside as first-line treatment for chronic myeloid leukemia. Acta Haematol., 89, 1993, 15-21.
3. GALE, R., HEHLMANN, R., ZHANG, M.: Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia. Blood, 91, 1998, 1810-1819.
4. GUILHOT, F., French CML Study Group: Interferon alpha and low-dose cytosine-arabinoside for the treatment of patients with chronic myelogenous leukemia in chronic phase. Semin. Hematol., 30, 1993, 24-25.
5. GUILHOT, F.,GUERCI, D., FIERE, J.:The treatment of chronic myelogenous leukemia by interferon and cytosine-arabinoside: Rational and design of the French trials. Bone Marrow Transplant., 17, 1996, 29-31.
6. GUILHOT, F., CHASTANG, G., MICHALLET, M.:Interferon alpha 2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N. Engl. J. Med., 337, 1997, 223-229.
7. HASFORD, J., PFIRRMANN, M., HEHLMANN, R.: A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alpha. J. Natl. Cancer Inst., 90, 1998, 850-858.
8. CHALMERS, E., CLARK, R.,FRANKLIN, I.: Treatment of chronic myeloid leukaema in first chronic phase with idarubicin and cytarabine: Mobilization of Philadelphia-negative peripheral blood stem cells. Leukemia Res., Suppl. 1, 21, 1997, 40, Abstract No. 156.
9. KANTARJIAN, H., O BRIEN, S., ANDERLINI, P.:Treatment of chronic myelogenous leukemia. Current status and investigational options. Blood, 87, 1996, 3069-3081.
10. SELLERI, C., MACIEJEWSKI, J., PANŠE, F.: Fas-mediated modulation of Bcr/abl in chronic myelogenous leukemia: Results in differential effects on apoptosis. Blood, 92, 1998, 981-989.
11. SILVER, R.: Chronic myeloid leukaemia. Practice guidelines. Trends Onco-Hematol., 6, 1998, 60-62.
12. THALER, J., HILBE, W.: Comparative analysis of two consecutive phase II studies with IFN alpha and INF/AraC in untreated chronic-phase CML patients. Bone Marrow Transplant., 17, 1997, 25-28.
13. TURA, S., BACCARANI, M., ZUFFA, E.: Interferon alfa 2a as compared with conventional chemoterapy for the treatment of chronic myeloid leukemia. N. Engl. J. Med., 330, 1994, 820-825.
14. WETZLER, M., KATARJIAN, M., KURZROCK, R.: Interferon - therapy for chronic myelogenous leukemia. Am. J. Med., 99, 1995, 402-411.